-+ 0.00%
-+ 0.00%
-+ 0.00%

Argus Research Upgrades Biogen to Buy, Announces $280 Price Target

Benzinga·10/29/2026 22:07:24
Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.